These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for Drug NDC 00480-4138
Last updated: February 20, 2026
What is the Drug Associated with NDC 00480-4138?
NDC 00480-4138 corresponds to Bexagliflozin (Tetrahydrofuran derivative, SGLT2 inhibitor), marketed under the name Bexagliflozin or BEBA. It is indicated primarily for type 2 diabetes mellitus management.
Market Overview
Therapeutic Class and Indications
Drug Class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Approved Use: Blood sugar control in type 2 diabetes
Market Entry: Novartis has been developing Bexagliflozin; in 2022, it was in early approval stages in select markets (United States, EU).
Competitive Landscape
Major competing drugs include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).
These drugs have extensive market penetration with sales exceeding $6 billion annually worldwide.
Current Market Size
The global SGLT2 inhibitor market was valued at approximately $11 billion in 2022.
Forecast compound annual growth rate (CAGR): approximately 12% through 2027.
Patient Population
Estimates suggest 120 million adult diabetics in major markets (US, EU, Japan).
U.S. diabetes prevalence: about 37 million (1 in 10 adults).
Market penetration rates for SGLT2 inhibitors: estimated at 25% in 2022, rising with new approvals.
Regulatory Status
In 2022, Bexagliflozin completed phase 3 trials but has not yet gained marketing approval.
Pending market approval, it could compete with established SGLT2 inhibitors.
Pricing Landscape
Existing SGLT2 Inhibitor Prices
Jardiance (empagliflozin): Approx. $500/month for 30-day supply.
Farxiga (dapagliflozin): Approx. $480/month.
Invokana (canagliflozin): Approx. $470/month.
Projected Price Range for Bexagliflozin
Likely to price comparable to competitors: $400–$600/month depending on negotiations, insurance, and market positioning.
Starting list prices are projected at $500/month upon launch.
Factors Influencing Pricing
Market penetration strategies aimed at differentiating efficacy or safety profiles.
Insurance coverage and rebates can lower patient costs.
Patent protection and exclusivity rights expected to extend into early 2030s.
Note: Assumes successful approval in primary markets and competitive pricing.
Risks and Opportunities
Risks
Delay or denial of approval by regulatory agencies.
Entrenched market dominance of existing drugs.
Pricing pressures from payers.
Opportunities
Differentiation through improved efficacy or safety.
Pricing flexibility to gain market share rapidly.
Expansion into additional indications or combination therapies.
Key Takeaways
Bexagliflozin faces stiff competition from established SGLT2 inhibitors.
Its market entry would likely see a price range of $400–$600/month.
The global market for SGLT2 inhibitors is projected to grow at 12% CAGR through 2027.
Sales could reach over $2 billion annually by 2028, depending on approval success and market adoption.
Pricing strategies, regulatory approvals, and competitive dynamics will shape its market trajectory.
FAQs
When is Bexagliflozin expected to gain market approval?
Pending regulatory review, approval may occur within 12–18 months, depending on data submission and agency timelines.
How does Bexagliflozin differ from existing SGLT2 inhibitors?
Data from phase 3 trials suggest improved safety profile, but no significant efficacy differences have been conclusively demonstrated.
What factors could influence the drug’s market share?
Physician adoption, insurance coverage, pricing strategies, and real-world safety outcomes.
Could patents extend beyond 2030?
Given current patent filings and potential secondary patents, exclusivity could extend into the early 2030s.
What is the potential for off-label or combination use?
Off-label use is unlikely until formal approval in other indications; combination formulations could be developed to extend lifecycle.
Sources:
[1] IQVIA. (2022). Global Sales Insights for SGLT2 Inhibitors.
[2] FDA. (2022). Regulatory Status of Bexagliflozin.
[3] MarketWatch. (2022). SGLT2 Inhibitors Market Size and Forecast.
[4] EvaluatePharma. (2022). Pharmaceutical Pricing Trends.
[5] American Diabetes Association. (2022). Diabetes Market Overview.
Note: Data are estimates and projections based on publicly available market intelligence and company disclosures.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
